Jefferies Highlights H2 2026 Pivotal Readouts in AtaiBeckley Pipeline
ATAI•Jefferies indicated that AtaiBeckley’s clinical pipeline has advanced toward several late-stage data catalysts, with pivotal trial readouts slated for the second half of 2026. The broker highlighted progression across multiple psychedelic therapy candidates, potentially unlocking near-term valuation inflection points for the venture.
1. Jefferies Marks Late-Stage Progress
Jefferies highlighted that AtaiBeckley’s joint pipeline has moved several lead candidates into late-stage clinical development, with pivotal data readouts expected in the second half of 2026. The update underscores progress across its psychedelic therapy programs and suggests potential upcoming valuation inflection points tied to these trial outcomes.
